Hemispherx Biopharma Enters Research Agreement With Defence Research & Development Canada (DRDC)
Hemispherx Biopharma, Inc. (AMEX: HEB) announces that they have entered into an agreement with Defence R&D Canada - Suffield (DRDC), an agency of the Canadian Department of National Defence, to evaluate the antiviral efficacy of its experimental therapeutic Ampligen(R) and Alferon(R) for protection against human respiratory influenza virus infection in well validated animal models.